Regeneron, Bayer’s Eye Drug Fulfills its Primary Goal
Regeneron Pharmaceuticals and Bayer HealthCare, a U. S. unit of Germany's Bayer, announced Thursday their experimental drug VEGF Trap-Eye, to treat retinal swelling brought on by diabetes, fulfilled its primary aim in a mid-stage study.
The drug VEGF Trap-Eye is being experimented for the condition known as diabetic macular edema -- the most prevalent cause of moderate vision loss in patients with diabetes. It is a disease of the retina that engulfs individuals with diabetes and can result in blindness.
The study, which took place over 24 weeks, compared VEGF Trap-Eye with laser therapy.
The study revealed that the patients receiving the drug fetched a significant improvement in visual acuity over 24 weeks compared to patients receiving the standard care, macular laser therapy.
The companies also said the drug was generally well tolerated, with no serious adverse events reported.
Shares of Regeneron, Tarrytown based company, closed at $30.46 Wednesday. Bayer HealthCare AG is based in Germany.
New Zealand News
- Porsche reportedly developing electric version of 718 sports car
- Tesla Model Y Performance becomes little bit more expensive to order in China
- Porsche’s recently unveiled Mission R Concept previews electric race cars of future
- Chinese manufacturer GAC’s Aion V e-SUV can charge 0-80% in just 8 minutes
- Oshidori International exits Japanese casino race, citing serious ethical irregularities
- Italian motorcycle racer Valentino Rossi enters e-bike business with VR46 MTB range
- Micro Mobility shows off production version of Microlino 2.0 and 3-wheeled e-scooter
- Chinese electric motorcycle maker Evoke Motorcycles to set up shops in Spain
- TenneT adds more electric BMWs to study use of EVs to support power grids
- Italy’s ASPI announces plans to install cross-country ultra-fast EV charging network